Comparison of renal actions of urodilatin and atrial natriuretic peptide

D. A. Hildebrandt, H. L. Mizelle, Michael W Brands, J. E. Hall

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

A 32-amino acid atrial natriuretic peptide (ANP)-like peptide, putatively synthesized by the kidney, has recently been isolated from human urine. This peptide, urodilatin (Uro), is structurally similar to the 28-amino acid ANP, suggesting that they might have similar actions on renal fluid and electrolyte excretion. The purpose of this study was to characterize the direct renal actions of low doses of Uro infusion and to compare them with the effects of equimolar intrarenal infusions of either ANP or the 24-amino acid atriopeptin III (AP III). Synthetic Uro was infused into the renal artery of pentobarbital sodium-anesthetized mongrel dogs (n = 8) at 0.14, 0.28, and 1.43 pmol · kg-1 · min-1 while renal perfusion pressure was servo-controlled at 100 mmHg. Uro infusion at 1.43 pmol · kg-1 · min-1 increased sodium excretion from an average control of 57.4 ± 10.1 to 159.0 ± 24.4 μeq/min. Uro infusion at the highest dose also increased potassium excretion (28.0 ± 4.5 vs. 40.4 ± 7.4 μeq/min), chloride excretion (56 ± 11 vs. 155 ± 22 μeq/min), and urine volume (0.54 ± 0.12 vs. 1.22 ± 0.25 ml/min). Fractional lithium excretion, a marker for proximal tubular sodium reabsorption, was not altered by Uro infusion, nor were urinary guanosine 3',5'-cyclic monophosphate excretion, glomerular filtration rate, or effective renal plasma flow changed. Equimolar infusions of these low doses of either α-human ANP (n = 6) or AP III (n = 8) had no effect on any of the measured variables. Thus, within the range of doses used in this study, Uro was a more effective natriuretic and diuretic agent than either ANP or AP III. Furthermore, the increase in renal fluid and electrolyte excretion with no changes in either renal hemodynamics or fractional lithium excretion supports the hypothesis that Uro inhibits tubular sodium reabsorption at a site beyond the proximal tubule.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume262
Issue number3 31-3
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Atrial Natriuretic Factor
Kidney
Sodium
Lithium
Amino Acids
Electrolytes
Urine
Effective Renal Plasma Flow
Natriuretic Agents
Peptides
Ularitide
Cyclic GMP
Renal Artery
Pentobarbital
Glomerular Filtration Rate
Diuretics
Chlorides
Potassium
Perfusion
Hemodynamics

Keywords

  • α-human atrial natriuretic peptide
  • atriopeptin III
  • blood pressure
  • glomerular filtration
  • guanosine 3',5'-cyclic monophosphate excretion
  • lithium
  • potassium
  • renal plasma flow
  • sodium

ASJC Scopus subject areas

  • Physiology

Cite this

Comparison of renal actions of urodilatin and atrial natriuretic peptide. / Hildebrandt, D. A.; Mizelle, H. L.; Brands, Michael W; Hall, J. E.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 262, No. 3 31-3, 01.01.1992.

Research output: Contribution to journalArticle

@article{7f45a796f0744f0ab3db958bf9d51890,
title = "Comparison of renal actions of urodilatin and atrial natriuretic peptide",
abstract = "A 32-amino acid atrial natriuretic peptide (ANP)-like peptide, putatively synthesized by the kidney, has recently been isolated from human urine. This peptide, urodilatin (Uro), is structurally similar to the 28-amino acid ANP, suggesting that they might have similar actions on renal fluid and electrolyte excretion. The purpose of this study was to characterize the direct renal actions of low doses of Uro infusion and to compare them with the effects of equimolar intrarenal infusions of either ANP or the 24-amino acid atriopeptin III (AP III). Synthetic Uro was infused into the renal artery of pentobarbital sodium-anesthetized mongrel dogs (n = 8) at 0.14, 0.28, and 1.43 pmol · kg-1 · min-1 while renal perfusion pressure was servo-controlled at 100 mmHg. Uro infusion at 1.43 pmol · kg-1 · min-1 increased sodium excretion from an average control of 57.4 ± 10.1 to 159.0 ± 24.4 μeq/min. Uro infusion at the highest dose also increased potassium excretion (28.0 ± 4.5 vs. 40.4 ± 7.4 μeq/min), chloride excretion (56 ± 11 vs. 155 ± 22 μeq/min), and urine volume (0.54 ± 0.12 vs. 1.22 ± 0.25 ml/min). Fractional lithium excretion, a marker for proximal tubular sodium reabsorption, was not altered by Uro infusion, nor were urinary guanosine 3',5'-cyclic monophosphate excretion, glomerular filtration rate, or effective renal plasma flow changed. Equimolar infusions of these low doses of either α-human ANP (n = 6) or AP III (n = 8) had no effect on any of the measured variables. Thus, within the range of doses used in this study, Uro was a more effective natriuretic and diuretic agent than either ANP or AP III. Furthermore, the increase in renal fluid and electrolyte excretion with no changes in either renal hemodynamics or fractional lithium excretion supports the hypothesis that Uro inhibits tubular sodium reabsorption at a site beyond the proximal tubule.",
keywords = "α-human atrial natriuretic peptide, atriopeptin III, blood pressure, glomerular filtration, guanosine 3',5'-cyclic monophosphate excretion, lithium, potassium, renal plasma flow, sodium",
author = "Hildebrandt, {D. A.} and Mizelle, {H. L.} and Brands, {Michael W} and Hall, {J. E.}",
year = "1992",
month = "1",
day = "1",
language = "English (US)",
volume = "262",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3 31-3",

}

TY - JOUR

T1 - Comparison of renal actions of urodilatin and atrial natriuretic peptide

AU - Hildebrandt, D. A.

AU - Mizelle, H. L.

AU - Brands, Michael W

AU - Hall, J. E.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - A 32-amino acid atrial natriuretic peptide (ANP)-like peptide, putatively synthesized by the kidney, has recently been isolated from human urine. This peptide, urodilatin (Uro), is structurally similar to the 28-amino acid ANP, suggesting that they might have similar actions on renal fluid and electrolyte excretion. The purpose of this study was to characterize the direct renal actions of low doses of Uro infusion and to compare them with the effects of equimolar intrarenal infusions of either ANP or the 24-amino acid atriopeptin III (AP III). Synthetic Uro was infused into the renal artery of pentobarbital sodium-anesthetized mongrel dogs (n = 8) at 0.14, 0.28, and 1.43 pmol · kg-1 · min-1 while renal perfusion pressure was servo-controlled at 100 mmHg. Uro infusion at 1.43 pmol · kg-1 · min-1 increased sodium excretion from an average control of 57.4 ± 10.1 to 159.0 ± 24.4 μeq/min. Uro infusion at the highest dose also increased potassium excretion (28.0 ± 4.5 vs. 40.4 ± 7.4 μeq/min), chloride excretion (56 ± 11 vs. 155 ± 22 μeq/min), and urine volume (0.54 ± 0.12 vs. 1.22 ± 0.25 ml/min). Fractional lithium excretion, a marker for proximal tubular sodium reabsorption, was not altered by Uro infusion, nor were urinary guanosine 3',5'-cyclic monophosphate excretion, glomerular filtration rate, or effective renal plasma flow changed. Equimolar infusions of these low doses of either α-human ANP (n = 6) or AP III (n = 8) had no effect on any of the measured variables. Thus, within the range of doses used in this study, Uro was a more effective natriuretic and diuretic agent than either ANP or AP III. Furthermore, the increase in renal fluid and electrolyte excretion with no changes in either renal hemodynamics or fractional lithium excretion supports the hypothesis that Uro inhibits tubular sodium reabsorption at a site beyond the proximal tubule.

AB - A 32-amino acid atrial natriuretic peptide (ANP)-like peptide, putatively synthesized by the kidney, has recently been isolated from human urine. This peptide, urodilatin (Uro), is structurally similar to the 28-amino acid ANP, suggesting that they might have similar actions on renal fluid and electrolyte excretion. The purpose of this study was to characterize the direct renal actions of low doses of Uro infusion and to compare them with the effects of equimolar intrarenal infusions of either ANP or the 24-amino acid atriopeptin III (AP III). Synthetic Uro was infused into the renal artery of pentobarbital sodium-anesthetized mongrel dogs (n = 8) at 0.14, 0.28, and 1.43 pmol · kg-1 · min-1 while renal perfusion pressure was servo-controlled at 100 mmHg. Uro infusion at 1.43 pmol · kg-1 · min-1 increased sodium excretion from an average control of 57.4 ± 10.1 to 159.0 ± 24.4 μeq/min. Uro infusion at the highest dose also increased potassium excretion (28.0 ± 4.5 vs. 40.4 ± 7.4 μeq/min), chloride excretion (56 ± 11 vs. 155 ± 22 μeq/min), and urine volume (0.54 ± 0.12 vs. 1.22 ± 0.25 ml/min). Fractional lithium excretion, a marker for proximal tubular sodium reabsorption, was not altered by Uro infusion, nor were urinary guanosine 3',5'-cyclic monophosphate excretion, glomerular filtration rate, or effective renal plasma flow changed. Equimolar infusions of these low doses of either α-human ANP (n = 6) or AP III (n = 8) had no effect on any of the measured variables. Thus, within the range of doses used in this study, Uro was a more effective natriuretic and diuretic agent than either ANP or AP III. Furthermore, the increase in renal fluid and electrolyte excretion with no changes in either renal hemodynamics or fractional lithium excretion supports the hypothesis that Uro inhibits tubular sodium reabsorption at a site beyond the proximal tubule.

KW - α-human atrial natriuretic peptide

KW - atriopeptin III

KW - blood pressure

KW - glomerular filtration

KW - guanosine 3',5'-cyclic monophosphate excretion

KW - lithium

KW - potassium

KW - renal plasma flow

KW - sodium

UR - http://www.scopus.com/inward/record.url?scp=0026605563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026605563&partnerID=8YFLogxK

M3 - Article

C2 - 1313650

AN - SCOPUS:0026605563

VL - 262

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 3 31-3

ER -